ヒトのエピスタティック相互作用はIL7Rスプライシングを制御し,多発性硬化症のリスクを増大させる
Gaddiel Galarza-Muñoz1, Farren B S Briggs2, Irina Evsyukova3
1Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA; Center for RNA Biology, Duke University, Durham, NC 27710, USA; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Cell
|March 25, 2017
まとめ
研究者は,多発性硬化症 (MS) のリスクに影響を与えるインタールイキン-7受容体α (IL7R) の主要な調節体としてDDX39Bを特定しました. DDX39Bの遺伝子変異は,IL7Rエクソン6のスプライシングに影響することで,MSの感受性に影響します.
科学分野:
- 神経免疫学
- 分子遺伝学
- 自己免疫 疾患
背景:
- 多発性硬化症 (MS) は,中枢神経系 (CNS) を標的とした自己免疫疾患です.
- 溶解性インタールキン7受容体アルファ (sIL7R) と関連している.
- 多発性硬化症の遺伝的基盤は 複雑な相互作用と 規制メカニズムを含んでいます
研究 の 目的:
- IL7R エクソン6の新しい調節体を特定する.
- MSの病原性におけるRNAヘリケーズDDX39Bの役割を調査する.
- 多発性硬化症のリスクに影響を与える 遺伝的・機能的相互作用の解明
主な方法:
- RNA スプライシング分析
- 遺伝子関連研究
- 遺伝子変異の機能分析
- エピスタシス分析
主要な成果:
- DDX39BはIL7Rエクソン6のスプライシングの活性化剤として特定され,それによってsIL7Rの生成を抑制する.
- DDX39Bの5' UTRの遺伝的変異は,DDX39Bの翻訳が低下し,MSのリスクが増加した.
- DDX39B変異体とIL7Rエクソン6型変異体の間では,有意な遺伝的および機能的エピスタシスが観察されました.
結論:
- DDX39BはIL7Rエクソン6のスプライシングの重要なレギュラーとして作用する.
- DDX39Bの遺伝的変異は,IL7Rスプライシングの調節によって,MSリスクに寄与する.
- この研究はヒトにおける生物学的エピスタシスを実証し,MSの病因に関するメカニズム的な洞察を提供している.
関連する概念動画
T Cell Types and Functions
2.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K
RNA Splicing
61.0K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.0K
Epistasis
50.7K
In addition to multiple alleles at the same locus influencing traits, numerous genes or alleles at different locations may interact and influence phenotypes in a phenomenon called epistasis. For example, rabbit fur can be black or brown depending on whether the animal is homozygous dominant or heterozygous at a TYRP1 locus. However, if the rabbit is also homozygous recessive at a locus on the tyrosinase gene (TYR), it will have an unshaded coat that appears white, regardless of its TYRP1...
50.7K
Epistasis Analysis
6.0K
Although Mendel chose seven unrelated traits in peas to study gene segregation, most traits involve multiple gene interactions that create a spectrum of phenotypes. When the interaction of various genes or alleles at different locations influences a phenotype, this is called epistasis. Epistasis often involves one gene masking or interfering with the expression of another (antagonistic epistasis). Epistasis often occurs when different genes are part of the same biochemical pathway. The...
6.0K
Multiple Allele Traits
38.5K
The Concept of Multiple Allelism
38.5K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
71
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
71


